Fisher & Paykel sells land. RBC raises target for Fisher & Paykel Healthcare stock

Published on 10/14/2026 at 04:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC raised its target to NZD 52.00 on September 16, 2026. Fiscal 2027 profit guidance is NZD 500 million-550 million for Fisher & Paykel Healthcare stock.

Land sale and earnings outlook

Fisher & Paykel Healthcare agreed to sell 13 hectares on October 5, 2026.
RBC raised its target to NZD 52.00 on September 16, 2026.
Fiscal 2027 profit guidance is NZD 500 million-550 million.
Half-year results are scheduled for November 26, 2026.

FPH, NZFAPE0001S2, Illustration mit AI erstellt.

Fisher & Paykel Healthcare (ISIN NZFAPE0001S2) agreed to sell 13 hectares of land for NZD 45.3 million on October 5, 2026, while RBC had raised its target to NZD 52.00 on September 16, 2026. The transaction links the medical-device maker's planned second campus with a future hospital in South Auckland.

Three events shape the story

On May 26, 2026, Yahoo Finance reported fiscal 2026 operating revenue of NZD 2.3 billion, up 14 percent, and net profit after tax of NZD 468.5 million, up 24 percent. On September 16, 2026, Investing.com said RBC upgraded the stock from Sector Perform to Outperform and lifted its target from NZD 39.00 to NZD 52.00. On October 5, 2026, Fisher & Paykel Healthcare announced the Drury land agreement.

What does the sale change?

The company will sell 13 hectares of its 105-hectare Karaka Road site to Health New Zealand for NZD 45.3 million. Settlement is expected between March and June 2027, subject to sale conditions, while Fisher & Paykel Healthcare will retain the remaining land for its second New Zealand campus.

The sale proceeds will be reported as an abnormal item in the income statement and are excluded from the company's fiscal 2027 earnings guidance. The fiscal 2027 estimate calls for operating revenue of NZD 2.45 billion-NZD 2.57 billion and net profit after tax of NZD 500 million-NZD 550 million, according to Yahoo Finance. That separation matters because the land transaction is a capital event, while the guidance reflects operating performance.

Results date and stock context

Fisher & Paykel Healthcare has scheduled its fiscal 2027 half-year results announcement for November 26, 2026, and listed an interim dividend in December 2026, according to its investor calendar. These dates put the next operating update before the settlement window for the land sale.

The company's business spans acute and chronic respiratory care, surgery and obstructive sleep apnea products sold in more than 120 countries. On October 14, 2026, the stock was trading at NZD 48.65 on the NZX, while market capitalization stood at NZD 28.6 billion. The quoted price was 0.31 percent below the previous NZX close of NZD 48.80.